

USSN 10/802,133

APR 20 2007

Docket No. 2852-US-CNT

Remarks/ArgumentsI. Status of the Claims

Claims 1-12 are currently pending in this application. Upon entry of this amendment, claims 1-12 are canceled without prejudice or disclaimer and new claims 13-24 introduced. Applicant retains the right to pursue the canceled claims in this or a continuing application. Thus, claims 13-24 are pending upon entry of this amendment.


The new claims find support throughout the specification, including for example, at p. 2, lines 14-30; page 5, lines 7-21; p. 11, lines 36-38; page 17, lines 16-17; and Example 10 (p. 26-27).

II. Response to Restriction Requirement

The undersigned thanks Examiner O'Hara for her courtesy in discussing the restriction requirement with the undersigned by telephone on April 16, 2007. As discussed during the conversation, Applicant is electing without traverse those claims in Group I, which originally included claims to kits containing antibodies to RANKL polypeptides, and submitting a new set of claims to antibodies to RANKL and methods for their use, thus maintaining similarity in subject matter with the original antibody kit claims.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 206-265-7858.

Respectfully submitted,



Scott L. Ausenhus
Attorney/Agent for Applicants
Registration No.: 42,271
Phone: (206) 265-7858
Date: April 20, 2007

Please send all further correspondence to:

22932

Customer No.